The "ESC 2024" provides a dynamic program showcasing cutting-edge data delivered by top experts in the field. The event culminates in an engaging Roundtable Discussion, where specialists will update you on groundbreaking new research and explore its implications for your region.
Dive into the latest advancements in Heart Failure, addressing its crucial role as a global health challenge. Discover the transformative potential of targeted therapies and gain valuable perspectives from leading cardiologists on recent treatment innovations and patient outcomes.
ESC 2024 Hybrid Congress Highlights:
| Section |
|
||||||||||||||||||||||
| 1 | Roundtable Discussion |
|
[watch now] | ||||||||||||||||||||
| Highlights | |||||||||||||||||||||||
| 1 | Hot Line |
|
[watch now] | ||||||||||||||||||||
| 2 | Guideline |
|
[watch now] | ||||||||||||||||||||
| 3 | Hypertension |
|
[watch now] | ||||||||||||||||||||
| 4 | Heart Failure |
|
[watch now] | ||||||||||||||||||||
| 5 | Coronary Artery Disease |
|
[watch now] |

What are the Key takeaways from Guideline updates at ESC
Moderator: Prof. John Amerena
Speaker: Prof. Ragy Hany Ibrahim
Prof. David Sim
Dr. Hani Sabbour
Dr. Genaro Menoza
TH-20152
EXP 21 Aug 2025
What’s new in HF management from ESC
Moderator: Prof. John Amerena
Speaker: Prof. Ragy Hany Ibrahim
Prof. David Sim
Dr. Hani Sabbour
Dr. Genaro Menoza
TH-20153
EXP 21 Aug 2025
Which was the most groundbreaking study readout at ESC
Moderator: Prof. John Amerena
Speaker: Prof. Ragy Hany Ibrahim
Prof. David Sim
Dr. Hani Sabbour
Dr. Genaro Menoza
TH-20154
EXP 21 Aug 2025
HELIOS-B study update
Prof. Tian Zhuang
TH-20141
EXP 3 Sep 2026
STOP-or-NOT trial, ABYSS trial
Prof. John Amerena
TH-20142
EXP 21 Aug 2025
Discusses-vutrisiran in patients with ATTR with CM
Dr. Hany Ragi
TH-20143
EXP 21 Aug 2025
Discusses HELIOS-B study in first and Eliminating Rheumatic heart disease from Africa- how can we do that?
Dr. Hany Ragi
TH-20144
EXP 21 Aug 2025
The HELIOS-B study update
Dr. Pedro Schwartzmann
TH-20330
EXP 21 Aug 2025
Discusses updates on late breaking trial STOP-or-NOT
Dr. Pedro Schwartzmann
TH-20331
EXP 21 Aug 2025
Talks about FINEARTS-HF and its clinical implication
Prof. David Sim
TH-20177|
EXP 21 Aug 2026
Discusses HELIOS-B study update
Dr. Ramzi Tabbalat
TH-20179
EXP 21 Aug 2026
Talks about the STEP program update
Dr. Mikhail Kosiborod
TH-20180
EXP 21 Aug 2026
Discusses the FINEARTS-HF update
Dr. Mikhail Kosiborod
TH-20181
EXP 21 Aug 2026
The 2024 ESC Guidelines for the Management of Elevated BP and Hypertension
Dr. Alta Schutte and Dr. Markus Schlaich
TH-20326
EXP 31 Aug 2025
The 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes
Dr. Jagdish Mohan
TH-20327
EXP 31 Aug 2025
Timing of antihypertensive treatment: The BedMed and BedMed-Frail RCTs
Dr. Alta Schutte and Dr. Markus Schlaich
TH-20145
EXP 21 Aug 2025
Discuss FDC in antihypertensive treatment: GMRx2 and QUADRO
Dr. Alta Schutte and Dr. Markus Schlaich
TH-20146
EXP 21 Aug 2025
New updates from GLP studies
Dr. Hani Sabbour
TH-20328
EXP 21 Aug 2025
Biomarkers to guide the treatment of heart failure: where are we going?
Dr. Hani Sabbour
TH-20329
EXP 21 Aug 2025
Updates from STEP program
Dr. Subodh Verma
TH-20172
EXP 21 Aug 2025
Discusses evidence in HF and call to action from ESC 2024
Dr. Subodh Verma
TH-20178
EXP 21 Aug 2025
Discusses the effects of Coronary Artery Calcium-Guided Statin Therapy on Atherosclerotic Progression in Intermediate-Risk People with Familial Coronary Artery Disease
Dr. Manuel Gaxiola
TH-20173
EXP 21 Aug 2025